Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson for Acute Vasoreactivity Testing in PH
NCT02220634Terminated
- Sponsor
- National Jewish Health
- Start
- Aug 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of regadenoson in pulmonary hypertension (PH), sponsored by National Jewish Health. Primary endpoint: Number of people at 5 years. Started Aug 2014; status: terminated.
02
Drugs
regadenoson
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02220634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220634.